التفاصيل البيبلوغرافية
| العنوان: |
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. |
| المؤلفون: |
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Sasahira, N., Hirano, K., Kogure, H., Kawakubo, K., Yagioka, H., Yashima, Y., Mizuno, S., Yamamoto, K., Arizumi, T., Togawa, O., Matsubara, S., Tsujino, T., Tateishi, K., Tada, M., Omata, M., Koike, K. |
| المصدر: |
British Journal of Cancer; 11/23/2010, Vol. 103 Issue 11, p1644-1648, 5p, 4 Charts, 2 Graphs |
| مصطلحات موضوعية: |
RENIN-angiotensin system, CARCINOGENESIS, TUMOR growth prevention, ENZYME inhibitors, ANGIOTENSIN I, ANGIOTENSIN II, CANCER patients, PANCREATIC cancer, ANTIHYPERTENSIVE agents |
| مستخلص: |
Background: The renin-angiotensin system (RAS) is thought to have a role in carcinogenesis, and RAS inhibition may prevent tumour growth.Methods: We retrospectively investigated the impact of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) in 155 patients with pancreatic cancer receiving gemcitabine monotherapy. Patients were divided into three groups: the ACEI/ARB group (27 patients receiving an ACEI or ARB for hypertension (HT)), the non-ACEI/ARB with HT group (25 patients receiving antihypertensive drugs other than ACEIs or ARBs), and the non-HT group (103 patients receiving no antihypertensive drugs).Results: Patient characteristics were not different, except for age and HT medications. Progression-free survival (PFS) was 8.7 months in the ACEI/ARB group, 4.5 months in the non-ACEI/ARB with HT group, and 3.6 months in the non-HT group. Overall survival (OS) was 15.1 months in the ACEI/ARB group, 8.9 months in the non-ACEI/ARB with HT group, and 9.5 months in the non-HT group. The use of ACEIs/ARBs was a significant prognostic factor for both PFS (P=0.032) and OS (P=0.014) in the multivariate analysis.Conclusions: The ACEIs/ARBs in combination with gemcitabine might improve clinical outcomes in patients with advanced pancreatic cancer. Prospective trials are needed to test this hypothesis. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder